జర్నల్ ఆఫ్ క్లినికల్ టాక్సికాలజీ
అందరికి ప్రవేశం

నైరూప్య

Drug-Induced Liver Injury Caused by Telotristat Etiprate

Karen P Geboes*, E Callebout, L Vandenabeele, Moura-Ribeiro S, Laurent S, De Man M, Van Vlierberghe H, Hoorens A

It is important to diagnose Drug Induced Liver Injury (DILI), because especially the acute hepatocellular-type carries a high risk of mortality and chronic injury. Liver failure has been described in patients receiving telotristat etiprate, a drug used to treat carcinoid syndrome in patients with neuroendocrine tumors, but was generally attributed to progression of liver metastases. We present a case of a patient with a diagnosis of drug-induced liver disease as assessed by the RUCAM score, the most commonly used tool for diagnosis of DILI and causality assessment. The patient suffered from an acute injury, grade of severity 1 and both biochemically and histologically hepatocellular injury was the suggested pattern. Patients on telotristat etiprate should be carefully monitored for liver function abnormalities and a high suspicion for a possible diagnosis of DILI is warranted.